当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.

Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.

Abstract：

:Several prognostic signatures have been identified for breast cancer. However, these signatures vary extensively in their gene compositions, and the poor concordance of the risk groups defined by the prognostic signatures hinders their clinical applicability. Breast cancer risk prediction was refined with a novel approach to finding concordant genes from leading edge analysis of prognostic signatures. Each signature was split into two gene sets, which contained either up-regulated or down-regulated genes, and leading edge analysis was performed within each array study for all up-/down-regulated gene sets of the same signature from all training datasets. Consensus of leading edge subsets among all training microarrays was used to synthesize a predictive model, which was then tested in independent studies by partial least squares regression. Only a small portion of six prognostic signatures (Amsterdam, Rotterdam, Genomic Grade Index, Recurrence Score, and Hu306 and PAM50 of intrinsic subtypes) was significantly enriched in the leading edge analysis in five training datasets (n = 2,380), and that the concordant leading edge subsets (43 genes) could identify the core signature genes that account for the enrichment signals providing prognostic power across all assayed samples. The proposed concordant leading edge algorithm was able to discriminate high-risk from low-risk patients in terms of relapse-free or distant metastasis-free survival in all training samples (hazard ratios: 1.84-2.20) and in three out of four independent studies (hazard ratios: 3.91-8.31). In some studies, the concordant leading edge subset remained a significant prognostic factor independent of clinical ER, HER2, and lymph node status. The present study provides a statistical framework for identifying core consensus across microarray studies with leading edge analysis, and a breast cancer risk predictive model was established.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Huang CC,Tu SH,Lien HH,Huang CS,Huang CJ,Lai LC,Tsai MH,Chuang EY

doi

10.1007/s10549-014-3104-6

subject

Has Abstract

pub_date

2014-09-01 00:00:00

pages

353-70

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

147

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.

    abstract：:Triple-negative breast cancers lack estrogen receptor α (ERα), progesterone receptor, and do not overexpress human epidermal growth factor receptor 2 (Her-2). They are neither susceptible to endocrine therapy nor to a therapy using the anti-Her-2 antibody, trastuzumab. Therefore, an efficient targeted therapy is warra...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-1968-x

    authors： Girgert R,Emons G,Gründker C

    更新日期：2012-07-01 00:00:00

  • Survival analysis of censored data: neural network analysis detection of complex interactions between variables.

    abstract：:Neural networks can be used as pattern recognition systems in complex data sets. We are exploring their utility in performing survival analysis to predict time to relapse or death. This technique has the potential to find easily some types of very complex interactions in data that would not be easily recognized by con...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00666212

    authors： De Laurentiis M,Ravdin PM

    更新日期：1994-01-01 00:00:00

  • Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.

    abstract：:The ability of the antiangiogenic agents TNP-470 and minocycline, singly or in combination, to potentiate the antitumor effects of several cytotoxic therapies was assessed in the murine EMT-6 mammary carcinoma as well as in two drug resistant sublines of that tumor designated EMT-6/CTX and EMT-6/CDDP. The antiangiogen...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00666043

    authors： Teicher BA,Holden SA,Dupuis NP,Kakeji Y,Ikebe M,Emi Y,Goff D

    更新日期：1995-01-01 00:00:00

  • A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.

    abstract：BACKGROUND:Vinorelbine (Navelbin; N) has proven to be active in patients with advanced breast cancer (ABC) and cyclophosphamide (C) and epirubicin (Epiadriamycin: E) are still among the main cytostatic agents against this tumor. On this basis was carried out a study to determine the activity and toxicity of the combina...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1023/a:1006477109230

    authors： Esteban E,de Sande G,Puertas J,Fra J,Palacio I,Vieitez JM,Fernández JL,Muñiz I,Modollel A,Carrasco J,Sala M,Lacave AJ

    更新日期：2000-07-01 00:00:00

  • International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases.

    abstract：:Recently, many centers have omitted routine axillary lymph node dissection (ALND) after metastatic sentinel node biopsy in breast cancer due to a growing body of literature. However, existing guidelines of adjuvant treatment planning are strongly based on axillary nodal stage. In this study, we aim to develop a novel ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s10549-013-2468-3

    authors： Meretoja TJ,Audisio RA,Heikkilä PS,Bori R,Sejben I,Regitnig P,Luschin-Ebengreuth G,Zgajnar J,Perhavec A,Gazic B,Lázár G,Takács T,Kővári B,Saidan ZA,Nadeem RM,Castellano I,Sapino A,Bianchi S,Vezzosi V,Barranger E,L

    更新日期：2013-04-01 00:00:00

  • Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.

    abstract：PURPOSE:Neutropenia is the most common toxicity of CDK4/6 inhibitors, causing frequent dose interruptions. However, CDK4/6 inhibitor-induced neutropenia shows a benign clinical course in contrast to that caused by chemotherapy. Here, we investigated the safety of a new dose scheme for palbociclib, which avoids dose del...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05750-y

    authors： Ham A,Kim MH,Kim GM,Kim JH,Kim JY,Park HS,Park S,Cho YU,Park BW,Kim SI,Sohn J

    更新日期：2020-08-01 00:00:00

  • Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.

    abstract：:The enumeration of circulating tumor cells (CTCs) provides important prognostic values in patients with metastatic breast cancer. Recent studies indicate that individual CTCs form clusters and these CTC-clusters play an important role in tumor metastasis. We aimed to assess whether quantification of CTC-clusters provi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3636-4

    authors： Mu Z,Wang C,Ye Z,Austin L,Civan J,Hyslop T,Palazzo JP,Jaslow R,Li B,Myers RE,Jiang J,Xing J,Yang H,Cristofanilli M

    更新日期：2015-12-01 00:00:00

  • Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients.

    abstract：:Gene-specific methylation alterations in breast cancer have been suggested to occur early in tumorigenesis and have the potential to be used for early detection and prevention. The continuous increase in worldwide breast cancer incidences emphasizes the urgent need for identification of methylation biomarkers for earl...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3276-8

    authors： Li Z,Guo X,Wu Y,Li S,Yan J,Peng L,Xiao Z,Wang S,Deng Z,Dai L,Yi W,Xia K,Tang L,Wang J

    更新日期：2015-02-01 00:00:00

  • Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.

    abstract：:Molecular profiles of asynchronous breast cancer metastases are of clinical relevance to individual patients' treatment, whereas the role of profiles in synchronous lymph node metastases is not defined. The present study aimed to assess individual biomarkers and molecular subtypes according to the St Gallen classifica...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2617-8

    authors： Falck AK,Bendahl PO,Chebil G,Olsson H,Fernö M,Rydén L

    更新日期：2013-07-01 00:00:00

  • Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging.

    abstract：INTRODUCTION:Axillary node fine needle aspiration cytology (FNAC) has the potential to triage women with operable breast cancer to initial nodal surgical procedure. Because of variability in the reported accuracy of this test its role and clinical utility in pre-operative staging remains controversial. METHODS:We retr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9355-0

    authors： Ciatto S,Brancato B,Risso G,Ambrogetti D,Bulgaresi P,Maddau C,Turco P,Houssami N

    更新日期：2007-05-01 00:00:00

  • Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).

    abstract：:Addition of epirubicin to adjuvant chemotherapy can provide important benefits for patients with early breast cancer, but the optimal dose remains unclear. Further improvements can be achieved with dose-dense regimens, but densification of fluorouracil/epirubicin/cyclophosphamide (FEC) has proved difficult, with FEC(6...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-008-9894-7

    authors： Kahán Z,Spanik S,Wagnerova M,Skacel T,Planko B,Fitzthum E,Lindner E,Soldatenkova V,Zielinski CC,Brodowicz T

    更新日期：2008-12-01 00:00:00

  • Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study.

    abstract：:The malignant biological behavior of breast cancer remains obscure on diagnostic images, although understanding the grade of such malignancy is important for selecting appropriate treatment. Therefore, malignancy grades in operable breast cancer were evaluated using positron emission tomography/computed tomography (PE...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-013-2687-7

    authors： Kadoya T,Aogi K,Kiyoto S,Masumoto N,Sugawara Y,Okada M

    更新日期：2013-09-01 00:00:00

  • ErbB-2 protein in sera and tumors of breast cancer patients.

    abstract：:We compared levels of erbB-2 oncoprotein among three groups: Group I included 60 asymptomatic women; Group II had 51 women with benign breast biopsies; and Group III had 67 women with node-negative breast cancer. Serological levels of erbB-2 protein were measured in all participants; tumor levels were measured for Gro...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006033214721

    authors： Breuer B,Smith S,Thor A,Edgerton S,Osborne MP,Minick R,Cody HS 3rd,Nowak E,Cortese A,Simmons RM,Carney WP,Brandt-Rauf PW

    更新日期：1998-06-01 00:00:00

  • Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread.

    abstract：:The early spread of tumor cells in primary breast cancer patients may occur either through lymphatic or hematogenous dissemination. Lymph node (LN) status and presence of disseminated tumor cells (DTC) in bone marrow (BM) are independent predictors of poor outcome. It is unknown which factors determine one or the othe...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1802-x

    authors： Hartkopf AD,Banys M,Krawczyk N,Staebler A,Becker S,Hoffmann J,Hahn M,Wallwiener M,Fehm T

    更新日期：2012-01-01 00:00:00

  • XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.

    abstract：:Published data on the association between Xeroderma Pigmentosum complementation group D (XPD) Lys751Gln polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association be...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-010-0813-3

    authors： Qiu LX,Yao L,Zhang J,Zhu XD,Zhao XM,Xue K,Mao C,Chen B,Zhan P,Yuan H,Hu XC

    更新日期：2010-11-01 00:00:00

  • Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.

    abstract：PURPOSE:Ki-67 has been clinically validated for risk assessment in breast cancer, but the analytical validation and cutpoint-definition remain a challenge. Intraclass correlation coefficients (ICCs) are a statistical parameter for Ki-67 interobserver performance. However, the maximum degree of variance among pathologis...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-05112-9

    authors： Denkert C,Budczies J,Regan MM,Loibl S,Dell'Orto P,von Minckwitz G,Mastropasqua MG,Solbach C,Thürlimann B,Mehta K,Blohmer JU,Colleoni M,Müller V,Klauschen F,Ataseven B,Engels K,Kammler R,Pfitzner BM,Dietel M,Fasching

    更新日期：2019-08-01 00:00:00

  • High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.

    abstract：:The purpose of the study was to compare breast-conserving therapy (BCT) and mastectomy (M) in BRCA1/2 mutation carriers. Women with invasive breast cancer and a pathogenic mutation in BRCA1 or BRCA2 were included in the study (n = 162). Patients treated with BCT (n = 45) were compared with patients treated with M (n =...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3115-3

    authors： Nilsson MP,Hartman L,Kristoffersson U,Johannsson OT,Borg A,Henriksson K,Lanke E,Olsson H,Loman N

    更新日期：2014-10-01 00:00:00

  • The impact of sharing results of a randomized breast cancer clinical trial with study participants.

    abstract：BACKGROUND:There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the process and impact of sharing results. We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and th...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-008-0057-7

    authors： Partridge AH,Wolff AC,Marcom PK,Kaufman PA,Zhang L,Gelman R,Moore C,Lake D,Fleming GF,Rugo HS,Atkins J,Sampson E,Collyar D,Winer EP

    更新日期：2009-05-01 00:00:00

  • A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

    abstract：:Complete remissions in patients with metastatic breast cancer using endocrine therapy or chemotherapy are infrequent. Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity. Based on laboratory experimen...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01805721

    authors： Allegra JC,Woodcock TM,Richman SP,Bland KI,Wittliff JL

    更新日期：1982-01-01 00:00:00

  • Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer.

    abstract：BACKGROUND:Gemcitabine and Vinorelbine both as a single agent or associated are active in advanced breast cancer patients as second line therapy, with low toxicity. In the elderly patients polichemotherapy is difficult for co-morbidity, but results with monotherapy are fewer. The use of this association as first line c...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-1000-1

    authors： Dinota A,Bilancia D,Romano R,Manzione L

    更新日期：2005-01-01 00:00:00

  • The declining use of axillary dissection in patients with early stage breast cancer.

    abstract：OBJECTIVES:To determine any changes in usage of axillary dissection over time from 1983 to 1993, and to characterize those patients who do not receive axillary node dissection. METHODS:A total of 129,946 female patients receiving cancer-directed surgery for early stage breast cancer, who were identified from the SEER ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006170811237

    authors： Du X,Freeman JL,Goodwin JS

    更新日期：1999-01-01 00:00:00

  • Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer.

    abstract：PURPOSE:Previous work found that lower BMI is associated with a pathologic complete response (pCR) following neoadjuvant chemotherapy for breast cancer. Relative dose intensity (RDI) of chemotherapy is an important marker of treatment tolerability. We hypothesized that patients with low BMI would have higher RDI than p...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05994-8

    authors： Usiskin I,Li F,Irwin ML,Cartmel B,Sanft T

    更新日期：2020-10-30 00:00:00

  • The effect of transcutaneous electrical nerve stimulation on postmastectomy skin flap necrosis.

    abstract：:Transcutaneous electrical nerve stimulation (TENS) is primarily used for pain reduction and is thought to activate neural fibers modifying vascular resistance and local blood flow influencing flap necrosis. This study aimed to delineate the effects of TENS on the viability of skin flaps created during mastectomy in br...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s10549-009-0335-z

    authors： Atalay C,Yilmaz KB

    更新日期：2009-10-01 00:00:00

  • Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.

    abstract：:Partner and localizer of BRCA2 (PALB2), plays an important functional role in DNA damage repair. Recent studies indicate that germline mutations in PALB2 predispose individuals to a high risk of developing familial breast cancer. Therefore, comprehensive identification of PALB2 germline mutations is potentially import...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3358-7

    authors： Downs B,Kim YC,Xiao F,Snyder C,Chen P,Fleissner EA,Becirovic D,Wen H,Sherman S,Cowan KH,Lynch HT,Wang SM

    更新日期：2015-05-01 00:00:00

  • MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

    abstract：:Node-positive breast carcinoma is associated with a poor prognosis. Some patients benefit from adjuvant chemotherapy but new treatment modalities should still be developed in order to further increase the cure rate in this patient group. Prognostic factors are needed to define patients for such studies. Here, the prog...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006326513176

    authors： Talvensaari-Mattila A,Pääkkö P,Turpeenniemi-Hujanen T

    更新日期：1999-12-01 00:00:00

  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract：:The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1429-y

    authors： Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期：2011-06-01 00:00:00

  • Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.

    abstract：:Tamoxifen has been used for the treatment of breast cancer since the 1970s, but is considered a carcinogen because it has been linked to liver cancer in rats and an increased risk of endometrial cancer in patients. In rats, DNA adducts appear to be responsible for carcinogenesis, but their contribution to carcinogenes...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006311214152

    authors： Hellmann-Blumberg U,Taras TL,Wurz GT,DeGregorio MW

    更新日期：2000-03-01 00:00:00

  • Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.

    abstract：:We examined the role of Mcl-1 and Bcl-2 expression in the induction of apoptosis. through blocking protein tyrosine kinase (PTK), protein kinase C (PKC), phosphatidylinositol 3-kinase (P13-K) and mitogen-activated protein kinase (MAPK)/Erk kinase (MEK) signaling pathways by various kinase inhibitors in MCF-7 breast ca...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1012564620853

    authors： Hu Y,Dragowska WH,Wallis A,Duronio V,Mayer L

    更新日期：2001-11-01 00:00:00

  • Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases.

    abstract：:Conflicting theories of epithelial carcinogenesis disagree on the clonal composition of primary tumors and on the time at which metastases occur. In order to study the spatial distribution of disparate clonal populations within breast carcinomas and the extent of the genetic relationship between primary tumors and reg...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9317-6

    authors： Torres L,Ribeiro FR,Pandis N,Andersen JA,Heim S,Teixeira MR

    更新日期：2007-04-01 00:00:00

  • GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis.

    abstract：:Cytosolic glutathione S-transferase comprises multiple isoenzymes; studies have principally examined mu-1 (GSTM1: null/present), theta-1 (GSTT1: null/present) and pi-1 (GSTP1 Ile105Val) gene polymorphisms concerning breast cancer risk. Regarding GSTT1 and GSTP1 polymorphisms, studies remain controversial and no recent...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-009-0520-0

    authors： Sergentanis TN,Economopoulos KP

    更新日期：2010-05-01 00:00:00